Dr. Myron Czuczman highlighted the significance of the recent U.S. Food and Drug Administration (FDA) approval of Lymphir ...

Nate, 55, a smoker, has seen three dermatologists for a rash that seems to be resistant to various treatments. He has complained that he has had a chronic bumpy and painful rash with pustules ...

A new study by researchers at Karolinska Institutet and Karolinska University Hospital shows that patients diagnosed with the rare skin cancers mycosis fungoides and Sézary syndrome face a ...

The US Food and Drug Administration has approved denileukin diftitox-cxdl (Lymphir, Citius Pharmaceuticals) for adults with relapsed or refractory stage 1-3 cutaneous T-cell lymphoma after at least ...

Extracorporeal photochemotherapy (ECP), also called photopheresis, is a type of pheresis in which aliquots of the patient's blood are removed, treated with a photosensitizing agent, and subjected to ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those ...

A nurse practitioner asks for an opinion regarding a skin lesion on a 39-year-old African American man. The lesion is located on the inner left thigh and is mildly pruritic. It measures an irregular ...

Increased risks seen based on twin cohort and case-cotwin studies. (HealthDay News) — Tattooed individuals have an increased risk for lymphoma and skin cancers, according to a study recently published ...

The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...